Peptide Briefs

BPC-157

Evidence grade: C — reviewed September 2026 Published controlled human trials: 0 · Published human pilot studies: 3 · Animal studies: 100+ Also known as: Body Protection Compound 157, PL 14736, Bepecin, pentadecapeptide BPC 157 Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids)

BPC-157 is a synthetic 15-amino-acid fragment of a protein found in human gastric juice. It is the most-studied peptide in the research-chemical market and one of the least studied in humans. More than a hundred animal papers, most from a single research group in Zagreb, describe accelerated healing of tendon, ligament, muscle, bone, gut, and blood vessels in rats. The published human record consists of three small pilot studies from one clinic, none with a control group, and one pharmaceutical trial that was never published. That gap between animal enthusiasm and human evidence is the whole story of this compound, and it is why the Ledger grades it C.

What BPC-157 is

The peptide was isolated in the early 1990s by Predrag Sikirić’s group at the University of Zagreb, who identified it as a stable fragment of a larger gastric protein. “Stable” matters: unlike most peptides, BPC-157 survives gastric acid, which is why the early work focused on oral administration for gut injury. Pliva, the Croatian pharmaceutical company, developed it under the code PL 14736 for inflammatory bowel disease in the early 2000s; that program was discontinued.

What the studies looked at

Gastrointestinal injury (rat). The earliest and largest body of work. Dozens of rat studies report protection or accelerated healing in models of gastric ulcer, colitis, fistula, and short-bowel syndrome, typically with oral or intraperitoneal dosing. Consistent within the Zagreb group; limited independent replication.

Tendon and ligament (rat, in vitro). Staresinic et al. (2003) reported faster healing of transected rat Achilles tendon and increased tendocyte growth in culture. Chang et al. (2011), an independent Taiwanese group, found BPC-157 promoted tendon fibroblast outgrowth and survival and identified a possible mechanism through FAK-paxillin signaling. These two are the most-cited papers behind the compound’s reputation for soft-tissue repair.

Muscle, nerve, and bone (rat). Multiple Zagreb-group papers report improved recovery from muscle crush injury, sciatic nerve transection, and segmental bone defects.

Vascular and “cytoprotective” effects (rat). A later line of work proposes BPC-157 acts on the nitric-oxide system and promotes collateral blood-vessel formation after vessel occlusion. This is the mechanism most often invoked to explain the breadth of effects; it remains a hypothesis.

Human studies. Three published, all in Alternative Therapies in Health and Medicine, all from Edwin Lee’s clinic in Orlando:

  • Lee & Padgett (2021): retrospective chart review of 16 patients who received intra-articular BPC-157 (some with thymosin β4) for knee pain; 14 reported relief 6–12 months later. No control group, no standardized diagnosis, no imaging follow-up.
  • Lee, Walker & Ayadi (2024): 12-patient pilot of intravesical BPC-157 for interstitial cystitis; no serious adverse effects reported.
  • Lee & Burgess (2025): 2-person pilot of intravenous BPC-157 reporting no adverse cardiac or renal effects.

Additionally, Pliva ran a Phase II placebo-controlled trial of PL 14736 enema in ulcerative colitis (reported as a 2005 conference abstract, never published in full) and registered a safety/PK study (NCT02637284) whose results were not published.

What the evidence does not show

  • No randomized, placebo-controlled trial of BPC-157 for any indication has been published.
  • No published human data on subcutaneous or oral use — the routes most discussed online.
  • No published human data on tendon, ligament, or muscle healing, the use for which it is best known.
  • No long-term human safety data. Animal toxicology reports are favorable but come almost entirely from the originating group.

Regulatory and sport status

  • FDA (US): In 2023 the FDA placed BPC-157 in Category 2 of its bulk drug substances list for compounding, citing safety concerns and insufficient data; it is not approved for any use and may not be compounded by pharmacies.
  • WADA: Prohibited in sport under section S0 (non-approved substances) since the 2022 list.
  • Legal supply: Sold in the US only as a research-use-only chemical.

Stability, storage, and handling in the laboratory

Lyophilized BPC-157 is stable at −20 °C for extended periods and tolerates short periods at room temperature during shipping. Once reconstituted in bacteriostatic water, laboratory practice is refrigeration at 2–8 °C and use within a few weeks; the peptide is notably acid-stable but, like all peptides, degrades with repeated freeze–thaw cycles and prolonged warmth. Purity is assessed by HPLC; identity by mass spectrometry. A certificate of analysis should state both, with a lot number.

Common questions

Is BPC-157 proven to heal tendons? In rats, repeatedly. In humans, it has never been tested for that purpose in a published study.

Why is the human evidence so thin if the animal data are so strong? The pharmaceutical development program (Pliva, early 2000s) stalled before publication, and no subsequent sponsor has funded a controlled trial. Most of what exists since is from a single clinic reporting its own patients.

Is it safe? The three human pilots reported no serious adverse effects in a combined 30 people. That is not a safety profile; it is an absence of red flags in a very small sample. The FDA’s Category 2 listing reflects the same gap.

Why does the Ledger grade it C when there are human studies? Because none of them were controlled. The Ledger’s B grade requires at least one published controlled human trial; retrospective chart reviews and uncontrolled pilots don’t meet that bar. See the Grade Key.

Could the grade change? Yes. A single published randomized controlled trial would move it to B regardless of outcome. We update the grade and the date when that happens.

Sources

  1. Sikirić P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327.
  2. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983.
  3. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.
  4. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.
  5. Sikirić P, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533.
  6. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435.
  7. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30:12-17. PMID 39325560
  8. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20-24. PMID 40131143
  9. Ruenzi M, et al. A multicenter, randomized, double-blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology. 2005;128:A584 (abstract).
  10. ClinicalTrials.gov. PCO-02 — Safety and Pharmacokinetics Trial. NCT02637284.
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. PMC12446177.
  12. US FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. 2023.
  13. USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. 2020; WADA Prohibited List 2022.

The Peptide Ledger is an independent reference published by the founders of Agape Compounds LLC. Nothing on this page is medical advice or a recommendation to use any compound outside a research setting. Grade reviewed September 2026.